The DNPEP Knockout HGC-27 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal cell population generated from the HGC-27 human gastric adenocarcinoma line, featuring targeted disruption of the DNPEP gene to abrogate aspartyl aminopeptidase function. This engineered knockout model serves as a versatile tool for loss-of-function studies investigating the molecular and cellular consequences of DNPEP deficiency in gastric cancer biology, without selection for clonal homogeneity.
The parental HGC-27 cell line is a poorly differentiated gastric adenocarcinoma originally isolated from a metastatic lymph node of a gastric cancer patient. These epithelial cells are widely utilized as a model for studying gastric cancer initiation, progression, and metastasis, as well as for evaluating therapeutic interventions targeting aberrant signaling networks in this malignancy.
At the molecular level, DNPEP encodes an aspartyl aminopeptidase that specifically removes N-terminal aspartate or glutamate residues from peptide hormones and other substrates, thereby contributing to peptide maturation and degradation pathways. Transcriptional control of DNPEP is mediated in part by the Sp1 transcription factor and is responsive to nutrient deprivation cues, linking peptidase expression to cellular metabolic status. Notably, the enzyme targets angiotensin II, and its activity can influence angiotensin II levels, which subsequently engage the angiotensin II type 1 receptor (AT1R) and downstream signaling cascades including VEGF-dependent pathways. DNPEP also interacts with broad-spectrum metalloprotease inhibitors and a variety of peptide substrates, positioning it as a node between peptidolytic regulation and angiogenic signaling.
In the HGC-27 gastric cancer context, loss of DNPEP activity leads to impaired catabolism of angiotensin II and potentially other N-terminal acidic peptides, resulting in altered ligand availability for AT1R and dysregulation of associated signal transduction. This disruption may impact gastric cancer cell proliferation, migratory capacity, and the tumor microenvironment??s angiogenic potential, as angiotensin II?CAT1R?CVEGF signaling is known to promote neovascularization and metastasis. Therefore, these polyclonal knockout cells provide a physiologically relevant platform to dissect the DNPEP-dependent peptidergic control of gastric adenocarcinoma behavior and to explore how nutrient-sensing mechanisms intersect with malignancy.
This cell model is suitable for a broad array of functional and mechanistic investigations, including Western blotting to confirm DNPEP ablation, aminopeptidase activity assays, proliferation (MTT/BrdU) and migration/invasion (Transwell) assessments, and angiogenesis assays such as tube formation. Transcriptomic analysis via RNA-seq can uncover global gene expression changes resulting from DNPEP disruption, while drug sensitivity profiling with aminopeptidase inhibitors allows evaluation of therapeutic vulnerabilities. Typical research applications encompass elucidating the role of peptide metabolism in gastric cancer progression and identifying novel targets for inhibiting tumor angiogenesis and metastasis. For further information and technical assistance, please contact Ascent Research.
